{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:54:44Z","timestamp":1770897284877,"version":"3.50.1"},"reference-count":37,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.2217\/imt-2015-0002","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T10:04:08Z","timestamp":1457949848000},"page":"479-488","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":125,"title":["The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis"],"prefix":"10.1080","volume":"8","author":[{"suffix":"Jr","given":"Pedro N","family":"Aguiar","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}]},{"given":"Ilka Lopes","family":"Santoro","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}]},{"given":"Hakaru","family":"Tadokoro","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}]},{"given":"Gilberto","family":"de Lima Lopes","sequence":"additional","affiliation":[{"name":"Oncocl\u00ednicas do Brasil group, S\u00e3o Paulo, Brazil"},{"name":"Department of Medical Oncology, Johns Hopkins University, Singapore"}]},{"given":"Bruno Andraus","family":"Filardi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}]},{"given":"Pedro","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Population Studies, Abel Salazar Biomedical Institute, University of Porto, Porto, Portugal"}]},{"given":"Giannis","family":"Mountzios","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Athens School of Medicine, Athens, Greece"}]},{"given":"Ramon Andrade","family":"de Mello","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal"},{"name":"Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"Clinical Research Center, Hospital Haroldo Jua\u00e7aba, & Department of Medical Oncology, Centro Oncol\u00f3gico S\u00e3o Mateus, Cancer Institute of Cear\u00e1, Rua Papi Junior, 1222, CEP 60430-235, Fortaleza-CE, Brazil"}]}],"member":"301","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"I.A.R.C. W.H.O. GLOBOCAN 2012: Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012 (2012). http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu098"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.9626"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834013510589"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0083"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv276"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60845-X"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.82"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1362"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520614666141110170259"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70074-4"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70054-9"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_3_22_1","article-title":"Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)","volume":"33","author":"Paz-Ares L","year":"2015","unstructured":"Paz-Ares L , HornL, BorghaeiHet al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO Annual Meeting33(Suppl.), Abstract LBA109 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_23_1","article-title":"First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression","volume":"33","author":"Gettinger S","year":"2015","unstructured":"Gettinger S , HellmannM, ShepherdFet al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. ASCO Annual Meeting33(Suppl.), Abstract 8025 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_24_1","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim Phase I results","volume":"32","author":"Antonia S","year":"2014","unstructured":"Antonia S , GettingerS, ChowLet al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim Phase I results. ASCO Annual Meeting32(Suppl.), Abstract 8023 (2014).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_25_1","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Rizvi N","year":"2015","unstructured":"Rizvi N , BrahmerJ, OuSet al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). ASCO Annual Meeting33(Suppl.), Abstract 8032 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_26_1","article-title":"Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC","volume":"33","author":"Antonia S","year":"2015","unstructured":"Antonia S , GoldbergS, BalmanoukianAet al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. ASCO Annual Meeting33(Suppl.), Abstract 3014 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_3_28_1","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a Phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy","volume":"33","author":"Gulley J","year":"2015","unstructured":"Gulley J , SpigelD, KellyKet al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a Phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. ASCO Annual Meeting33(Suppl.), Abstract 8034 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_29_1","article-title":"Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR)","volume":"33","author":"Spira A","year":"2015","unstructured":"Spira A , ParkK, Mazi\u00e8resJet al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR). ASCO Annual Meeting33(Suppl.), Abstract 8010 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8029"},{"key":"e_1_3_3_31_1","article-title":"Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)","volume":"33","author":"Liu S","year":"2015","unstructured":"Liu S , PowderlyJ, CamidgeDet al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting33(Suppl.), Abstract 8030 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_32_1","article-title":"The role of biomarkers in improving clinical trial success: a study of 1,079 oncology drugs","volume":"33","author":"Lopes G","year":"2015","unstructured":"Lopes G , ParkerJ, WillanAet al. The role of biomarkers in improving clinical trial success: a study of 1,079 oncology drugs. ASCO Annual Meeting33(Suppl.), Abstract e17804 (2015).","journal-title":"ASCO Annual Meeting"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_3_3_34_1","unstructured":"Higgins JPT GreenS. Cochrane handbook for systematic reviews of interventions (2011). http:\/\/handbook.cochrane.org\/."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e3181b1c99f"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"issue":"3","key":"e_1_3_3_38_1","first-page":"462","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis","volume":"7","author":"Pan ZK","year":"2015","unstructured":"Pan ZK , YeF, WuX, AnHX, WuJX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J. Thorac. Dis.7(3), 462\u2013470 (2015).","journal-title":"J. Thorac. Dis."},{"key":"e_1_3_3_39_1","article-title":"PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer","volume":"33","author":"Owonikoko T","year":"2015","unstructured":"Owonikoko T , KowalskiJ, KimSet al. PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer. ASCO Annual Meeting33(Suppl.), Abstract 7551 (2015).","journal-title":"ASCO Annual Meeting"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2015-0002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:21:32Z","timestamp":1715991692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2015-0002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.2217\/imt-2015-0002"],"URL":"https:\/\/doi.org\/10.2217\/imt-2015-0002","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}